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Accepted 17 January 2012AbstractOsteoporotic patients with existing fractures are at substantially higher risk of subsequent fractures than those free of fractures. Given the lack
of head-to-head comparison trials, indirect comparison of various antiosteoporosis treatments may be an alternative way to develop a preliminary
idea. The objective of this study is to conduct a systematic review of antiosteoporosis treatment clinical trials that have investigated on patients
with existing fractures. All the results of randomized placebo-controlled trials of the available antiosteoporosis treatments, including
bisphosphonates, selective estrogen receptor modulators, calcitonin, strontium ranelate, and agents derived from parathyroid hormone, on
patients with existing fractures were summarized. All the antiosteoporotic agents had significant efficacy in increasing lumbar spine bone
mineral density and reduction in the occurrence of any new vertebral fractures. All interventions provided gains in quality-adjusted life-years
compared with patients without treatment. The results from an indirect comparison must be interpreted with caution due to heterogeneous study
design, discrepancies of disease severity at baseline, and differences in analytical methodologies. The devastating complications subsequent to
osteoporotic fractures create medical and financial burdens; therefore, treatment of patients with osteoporotic fractures should be positioned in
the top priority in the utilization of medical resources.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Keywords: bone; fracture; osteoporosis; postmenopausal womenIntroduction
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http://dx.doi.org/10.1016/j.tjog.2012.04.001fragility and subsequent fracture [1]. With the aging of the
world’s population, the incidence of osteoporosiswill inevitably
increase year by year. Osteoporotic fracture leads to debilitating
health outcomes and consequently a considerable economic
burden on the health care system. In the United States,
approximately 10 million Americans are diagnosed with oste-
oporosis each year, leading to a substantial financial burden of
annual direct medical costs estimated at $17 billione20 billion
[2]. In Europe, the estimated costs of treating osteoporotic
fractures in women by 2050 will be V76.7 billion [3]. Asia has
the highest increment in the elderly population; therefore,
osteoporotic fracture should grow to be a noticeable health issue.
The incidence rate of hip fractures in Asia could rise to 45% bycs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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in females and males above 65 years of age are approximately
20% and 12.5%, respectively [5]. The annual reported cases of
hip fractures in the Taiwanese populations aged 65 years or older
increased from 8384 in 1996 to 13,075 in 2002, with overall
incidence increment of 30% during 7 years [6].
Advancing age, lack of estrogen, vitamin D and/or calcium
deficiency, low body weight or low body mass index (BMI),
immobility, current smoking, excessive alcohol consumption,
endocrine diseases, the use of certain medications (such as
glucocorticoids, gonadotropin-releasing hormone agonists, or
chemotherapy-induced early menopause), surgical interven-
tion, and family history have been described as risk factors of
osteoporosis [7e15]. Some factors, such as poor postural
balance, visual impairment, frailty, or sedation medication,
also put patients at a risk of osteoporotic fracture [16].
There is ample evidence suggesting that an existing
osteoporosis-induced fracture heralds another impending
fracture [17e20], and many subsequent fractures have
occurred within 1 year of the original incident [21]. The
relative risk of refracture events among patients with prevalent
vertebral fracture was reported to be 4.7e7.4 [19,22,23].
Therefore, patients with osteoporosis-related fractures should
be treated more vigorously.
Pharmacologic therapies to treat osteoporosis have been
extensively explored; however, a comparison of fracture risk
reduction among therapies is difficult due to the lack of head-Fig. 1. Mechanisms of action of antiosteoporosis treatments. Bone mass and bone
bone remodeling. Bone remodeling is regulated by two cell types: osteoclasts, whi
new bone matrix synthesis. Osteoporosis is a disease characterized by reduced bon
formation. Bisphosphonates, selective estrogen receptor modulators (SERMs), and c
by reducing bone turnover. The exact mechanism of action of strontium is not know
hormone (PTH) lead to anabolic effects on the skeleton if administered intermittentl
properties for osteoblastic cells and decreasing osteoblastic apoptosis.to-head studies. Patients with existing fracture are at
substantially higher risk of subsequent fracture than those free
of fractures [24]. The objective of this review is to focus on
those clinical trials whose participants had a fracture at study
entry, and to summarize the results with respect to changes in
bone mineral density (BMD), bone turnover markers, fracture
risk, quality of life, and cost-effectiveness. Consideration of
these results can aid in making the most appropriate judgment
when selecting the optimal treatment plan, and in attaining the
most beneficial effect in the prevention of subsequent fracture.
For this manuscript, a nonsystematic Pubmed search of
published data was performed with the following search terms:
osteoporosis and fracture. The search was conducted from
1995 to 2000 and used only articles published in English.
Pharmacologic therapies for osteoporosis
The available antiosteoporosis treatments include
bisphosphonates, selective estrogen receptor modulators
(SERMs), calcitonin, strontium ranelate, and agents derived
from parathyroid hormone (PTH). Fig. 1 illustrates the
mechanism of action of these antiosteoporosis medications.BisphosphonatesBisphosphonates currently approved for the prevention and
treatment of osteoporosis is a class of pyrophosphatequality are maintained by a continuous renewal of the matrix, a process called
ch resorb the calcified bone matrix, and osteoblasts, which are responsible for
e strength which results from an imbalance in bone resorption relative to bone
alcitonin are classical inhibitors of bone resorption that restore skeletal balance
n but anti-resorptive effects have been shown. Agents derived from parathyroid
y and at low dose. The main anabolic actions of PTH involve having mitogenic
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number of bisphosphonates have been synthesized, and the
presence of a nitrogen moiety is directly related to the potency
of the bisphosphonate agent [26]. Bisphosphonates have
a strong affinity for hydroxyapatite crystals in bone and inhibit
osteoclast activity and recruitment via blocking the enzyme
farnesyl diphosphate synthase in the mevalonate pathway [26].SERMsSERMs are nonsteroidal agents that bind on the estrogen
receptor (ER) [27]. Unlike estrogens, which are uniformly
agonists, and anti-estrogens, which are uniformly antagonists,
the SERMs exert selective agonist or antagonist effects on
various estrogen target tissues [28]. A given target tissue has
its own distinct ER expression. The underlying mechanisms of
the unique pharmacology of SERMs are mainly based on the
bulky side-chain which leads to a differential ER conformation
on ligand binding or a differential interaction between cor-
egulator proteins and ER [28,29].CalcitoninCalcitonin is an endogenous polypeptide hormone
produced in humans primarily by the parafollicular cells of the
thyroid [30]. The physiologic function of calcitonin is mainly
to reduce blood calcium via the metabolic pathway in bone,
intestines, and kidney. In bone, calcitonin inhibits resorption
activity by decreasing osteoclast formation and suppressing
osteoclast attachment [31].Strontium ranelateStrontium ranelate is a combination of an organic moiety
(ranelic acid) and two atoms of stable nonradioactive stron-
tium [32]. Nonclinical in vitro data indicate that strontium
increased bone formation in certain preosteoblastic cell
systems, and inhibited the bone resorption activity of osteo-
clasts [33]. However, strontium’s mechanism of action is not
known. Available in vivo studies in ovariectomized animals
provide weak support only in terms of efficacy for the intended
clinical use [34]. It has been demonstrated that strontium is
predominately distributed into calcified tissues [35].TeriparatideTeriparatide (1-34PTH) is a recombinant formulation
compromising the first 34 N-terminal amino acids of PTH that
increases bone mass and improves bone microstructure via
a daily subcutaneous administration. PTH-stimulates bone
formation and resorption and can increase or decrease bone
mass, depending on the mode and dose of administration [36].
Continuous administration can lead to deleterious conse-
quences for the skeleton. However, intermittent low dose
administration of PTH results in an increase in the number and
activity of osteoblasts, leading to an increase in bone mass and
an improvement in skeletal architecture [37].Review of antiosteoporosis treatment trials
Table 1 [14,16,29,30,33e35,37] is a summary of the clin-
ical trials that have included postmenopausal women with pre-
existing fracture as a subpopulation.Bisphosphonates
Alendronate
The Fracture Intervention Trial (FIT) was a randomized,
double-masked, placebo-controlled trial testing the hypothesis
that alendronate reduces fracture rates in women with osteo-
porosis [38]. The FIT had two arms: the vertebral fracture arm
and the clinical fracture arm. The vertebral fracture arm
included 2027 women with osteoporosis and at least one pre-
existing vertebral fracture. Baseline vertebral fractures were
defined as any of the ratios of vertebral heights being more
than 3 standard deviations (SDs) below the mean population
norm for that vertebral level. A new morphometric vertebral
fracture was defined as a decrease of 20% and greater than 4
mm in any vertebral height from baseline to end of the study.
Risedronate
The Vertebral Efficacy with Risedronate Therapy (VERT)
trial was a randomized, double blind, placebo-controlled trial
testing the efficacy and safety of risedronate in post-
menopausal women with established osteoporosis [24,39]. The
VERT Multinational study (VERT-MN) enrolled 1226 post-
menopausal women at 80 centers in Europe and Australia; the
patients were required to have two or more prevalent vertebral
fractures [24]. The VERT North American Study (VERT-NA)
included 2458 women younger than 85 years with at least one
vertebral fracture at baseline and who were enrolled from 110
centers in North America [40]. Both trials had extension
studies with an additional 2 years of treatment to determine the
long-term efficacy and safety of risedronate.
Patients in the VERT-MN study were randomized to
receive risedronate 2.5 or 5 mg/day or a placebo; the 2.5 mg
group was discontinued by protocol amendment after 2 years.
The identification of prevalent or incident fractures was based
on quantitative and semiquantitative assessments [41,42]. An
incident new vertebral fracture was defined quantitatively as
a loss of 15% or more in the anterior, posterior, or middle
vertebral height in a vertebra that was normal at baseline, and
semiquantitatively as a change from grade 0 (normal) to
grades 1 (mild), 2 (moderate), or 3 (severe). A worsening
vertebral fracture was recorded if there was a change of 4 mm
or more in vertebral height or a change in grade in a previously
fractured vertebra.
Ibandronate
The oral iBandronate Osteoporosis Vertebral Fracture Trial
in North America and Europe (BONE) was a multinational,
double-blind, placebo-controlled, randomized trial composed
of 2946 postmenopausal women with one to four prevalent
vertebral fractures and a BMD T-score less than e2.0 in at
least one vertebra [43]. Participants were randomly assigned to
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a daily dose of 2.5 mg, or intermittent oral ibandronate with
20 mg every other day for 12 doses every 3 months. The
diagnosis of fractures was based on morphometric criteria and
was further confirmed by qualitative assessment. A new
vertebral fracture was diagnosed with a relative height
reduction of at least 20% and an absolute decrease of at least 4
mm in any vertebral body height from the baseline radiograph.SERMs
Raloxifene
Raloxifene hydrochloride, a SERM, is a nonsteroidal ben-
zothiophene that has similar binding ability to ERs as
estrogen. Raloxifene is the only SERM currently approved for
the prevention and treatment of osteoporosis. The Multiple
Outcomes of Raloxifene Evaluation (MORE) study was
a multicenter, randomized, blinded, placebo-controlled trial
examining the effect of raloxifene on the skeleton [22]. A total
of 7705 postmenopausal women were enrolled into this study.
Prior to randomization, patients were divided into two study
groups, based on any existing vertebral fractures at the time of
radiographic screening. Eventually, 2641 women had a low
bone mineral density T score and 1 or more moderate or
severe vertebral fractures or two or more mild vertebral frac-
tures. The BMD entry criteria depended on the T score of
femoral neck or lumbar spine BMD of less than e2.5.
Vertebral fractures were evaluated using a semiquantitative
scale for each vertebra (T4eL4), with grading scores of 0 to 3
for none to severe fractures. A mild vertebral fracture corre-
sponded to a 20%e25% reduction in height, and a moderate
vertebral fracture corresponded to a 25%e40% reduction from
expected vertebral height. A new fracture was defined as an
incident fracture (grade change of at least one as well as
a quantitative definition of a decrease in anterior, mid, or
posterior vertebral height of at least 20%, and at least 4 mm),
which was absent at baseline.
Within each substudy, women were randomly assigned into
treatment groups with either a placebo, or 60 mg or 120 mg of
raloxifene. There was a significantly lower incidence of frac-
tures in the women given 120 mg of raloxifene compared with
those treated with 60 mg of raloxifene; however, 60 mg per
day has been approved as a treatment dose of raloxifene, so we
will just focus on the anti-fracture results from this subgroup.
Calcitonin
The Prevent Recurrence of Osteoporotic Fractures
(PROOF) study was a randomized, double-blind, placebo-
controlled, multicenter trial investigating the effect of nasal
spray calcitonin on reducing the risk of recurrent vertebral
fractures [44]. A total of 1255 women with osteoporosis who
had been postmenopausal for at least 1 year and had one to
five prevalent thoracic or lumbar compression fractures were
included. The definition of osteoporosis was based on lumbar
spine BMD at least two SDs below normal for women aged 30
years. Baseline vertebral fractures were defined as having
a ratio of vertebral heights more than three SDs below the
157M.-H. Cheng et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 153e166mean population norm for that vertebral level by quantitative
morphometry, and a fracture grade 1 or greater using a semi-
quantitative evaluation. A new vertebral fracture was defined
as a decrease of 20% and at least 4 mm in the height of any
vertebral body by quantitative morphometry, as well as
a change in the fracture grade from 0 to 1 or greater by
semiquantitative evaluation.
This study participants were randomly assigned to receive
a placebo or salmon calcitonin at a daily dose of 100, 200, or
400 IU. The standardized radiographic evaluation revealed
that 334 enrolled patients did not meet the inclusion criteria of
one to five vertebral fractures, and one-third of them had no
vertebral fractures. This study was not designed to have power
to discriminate between doses, and 200 IU per day was
approved as the dose for treating osteoporosis. Although there
were a relatively small number of patients for an anti-fracture
assessment, we will still use the 200 IU/d result as a compar-
ison reference.
Strontium ranelate
The Spinal Osteoporosis Therapeutic Intervention (SOTI)
was a 5-year multicenter, placebo-controlled, randomized,
double blind trial [45]. The study was designed to evaluate the
effect of strontium ranelate on the incidence of new vertebral
fractures in 1649 postmenopausal women with osteoporosis
who had previously had one or more vertebral fractures.
Patients were randomized to receive 2 g of oral strontium
ranelate per day or a placebo, and clinical effectiveness was
evaluated during a 3-year period. Vertebral radiographs were
obtained annually, and measurements of bone mineral density
were performed every 6 months.
The other trial was the Treatment of Peripheral Osteopo-
rosis Study (TPOS), which was undertaken to assess the effect
of strontium ranelate on non-vertebral and vertebral fractures
in postmenopausal women with osteoporosis in a 5-year,
double-blind, placebo-controlled trial [46]. A total of 5,091
postmenopausal women with osteoporosis were randomized to
receive either strontium ranelate at 2 g/day or a placebo for
5 years.
Teriparatide
The Fracture Prevention Trial (FPT) was a multicenter,
randomized, placebo-controlled trial testing the effect of ter-
iparatide treatment on postmenopausal women with prior
vertebral fractures [47]. All participants underwent radiog-
raphy of the thoracic and lumbar spine at baseline, to grade
vertebrae as normal, mildly, moderately, or severely deformed
based on a decrease in vertebral height of approximately
20%e25%, 26%e40%, or more than 40%, respectively. Only
those women with at least one moderate fracture or two mild
fractures were eligible for enrollment. The mean BMD of the
spine was 2.6 SDs below the mean value of normal young
white women. A new fracture was reported when a normal
vertebra became deformed, but not with a worsening of pre-
existing deformities.
A total of 1637 women were randomly assigned into three
arms: placebo, or teriparatide at a dose of 20 mg/day or 40mg/day. Since 20 mg is used as the treatment dose for osteopo-
rosis, this review will focus on the effect of the 20 mg daily dose.
Effects on bone markers and bone tissue
Most available therapies, including bisphosphonates,
raloxifene, and calcitonin, decrease the rate of bone turnover
by suppressing the level of bone resorption markers coupled
with a subsequent reduction of bone formation activity. Data
from the SOTI trial indicated strontium ranelate had an
uncoupling effect on the bone remodeling process, with
decreased bone resorption markers, but a slight increase in
bone formation markers compared with placebo therapy [48].
There was no available information in terms of changes in
bone turnover markers from the FPT trial.
The effects on bone remodeling or the mechanisms of
action can be also obtained from bone histomorphometric
parameters of bone turnover, although the study design or
a small sample size probably limits the application of this kind
of survey. Histologic and histomorphometric analyses of
baseline and post-treatment biopsy samples in the VERT-NA,
as well as an extension study with an additional 2-year treat-
ment of risedronate, showed a reduction of bone turnover
without any evidence of pathologic findings [44,48].
Through data on comparative changes in bone biopsy or
biochemical markers of bone turnover, some head-to-head
studies have provided us a more precise idea about the mecha-
nism of action in the bone tissue. In the comparative study of
teriparatide and alendronate, not surprisingly, bone formation
indices of histomorphometry were significantly greater in the
teriparatide group than in the alendronate group [49]. A study
comparing the effects of teriparatide and strontium ranelate on
bone biopsies and biochemical markers of bone turnover
confirmed that the bone-forming activity (anabolic effect) of
teriparatide was superior to that of strontium ranelate treatment
[50]. However, a small, but significant reduction of bone
formation marker procollagen type I N-propeptide (PINP) was
found with strontium ranelate treatment.
Summary of effects on bone markers and bone tissue
Bisphosphonates, raloxifene, and calcitonin have a direct
inhibitory effect on osteoclastic bone resorption, although
coupled subsequently with a suppression of osteoblastic bone
formation. The function of strontium ranelate on stimulating
bone formation is equivocal due to the lack of robust evidence.
Based on the change in biochemical bone formation markers
as well as the proof of bone biopsy, it is reassuring that ter-
iparatide is an effective bone-formation agent. Table 2
[14,30,33e35] is a summary of the bone turnover marker
changes with the anti-osteoporotic therapies used in the
prospective clinical trials.
Effects on BMD
All the antiresorptive agents were of the same treatment
duration. The percentage of BMD changes in the PROOF trial
Table 2
Summary of bone turnover markers change of antiosteoporotic therapies from prospective clinical trials.
Agent Study population Bone turnover markers % change of bone turnover
markers at study endpoint
p value Reference
Bisphosphonate
Alendronate NA NA
Risedronate 32% of the total
study population
Serum BSAP 33% at Y 3 (7%placebo) NA 30
Deoxypyridinoline/creatinine 26% at Y 3 (1%placebo) NA
Ibandronate CTX/creatinine 65.3% at Y 3 (continuous 2.5 mg/d) from baseline
52.7% at Y 3 (intermittent 20 mg)
<0.0001 33
NTX/creatinine 68.3% at Y 3 (continuous 2.5 mg/d)
59.2% at Y 3 (intermittent 20 mg)
<0.0001
Serum osteocalcin 35.8% at Y 3 (continuous 2.5 mg/d)
40.9% at Y 3 (intermittent 20 mg)
<0.0001
Raloxifene Serum osteocalcin 17.7% at Mo 36 (tx26.3, placebo8.6%) <0.001 14
Urinary CTX 25.9% at Mo 36 (tx34.0, placebo8.1) <0.001
Calcitonin Serum CTX 12% (vs placebo) 0.01 34
Serum BSAP Decreased but NA <0.05
Serum osteocalcin Decreased but NA NS
Strontium Ranelate 20% of the total
study population
Serum CTX 12.2% at Mo 3 (vs placebo) <0.001 35
Serum BSAP þ8.1 at Mo 3 <0.001
Teriparatide NA NA
BSAP ¼ bone-specific alkaline phosphatase; CTX ¼ C-telopeptide of the a-chain of type I collagen; NA ¼ not applicable; NTX ¼ N-telopeptide of the a-chain of
type I collagen.
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that the value of reference for BMD change was the placebo
instead of the baseline in the BONE and MORE trials [22,42].
In summary, all of the anti-osteoporotic agents had signif-
icant efficacy in increasing lumbar spine BMD. The
bisphosphonates had a similar effect on changes in BMD,
ranging from 5.9% for risedronate to 6.5% for ibandronate
2.5 mg/day [24,38,42]. Among all the anti-resorptive agents,
strontium ranelate had the most apparent impact on BMD, notTable 3
Summary of BMD percentage changes of antiosteoporotic therapies from prospec
Agent BMD measurement BMD at
baseline
(T-score)
Percentage
Lumbar
spine
Femoral
neck
Trochanter Inte
Bisphosphonate
Alendronate 3 y 6.2*** 4.1*** 6.1***
Risedronate 3 y (VERT-NA) 5.4*y 1.6*y 3.3*y
3 y (VERT-MN) 2.8 5.9***y 3.1***y 6.4***y
5 y (VERT-MN) 9.3* 2.2* 5.7*
Ibandronate 3 y 2.8 6.5****a
5.7****b
2.8****a
2.4****b
5.5****a
5.2****b
Raloxifene 3 y 2.6*** 2.1***
Calcitonin 5 y 1.2** NS NS
Strontium
Ranelate
3 y 12.7***y 7.2***y
Teriparatide 21 mo 2.6 9.7***y 2.8***y 3.5***y 2.6
BMD ¼ bone mineral density.
***p < 0.001 versus placebo.
*yp < 0.05 versus baseline and placebo.
*p < 0.05 versus baseline.
***yp < 0.001 versus baseline.
****p < 0.0001 versus baseline.
**p < 0.01 versus placebo.
a Continuous ibandronate 2.5 mg/day; b Intermittent ibandronate 20 mg everyonly at the lumbar spine but also at the femoral neck and hip
bone [44,45]. However, the striking increment of BMD was
probably associated with the high atomic mass of strontium,
while strontium atoms replaced calcium atoms in the bone
hydroxyapatite crystals. Compared with other antiosteoporosis
agents, teriparatide, with bone-formation preference, achieved
a remarkable elevation in BMD within a relatively short
treatment period [36,41]. Table 3 [14,16,29,30,33e35,37,42]
summarizes the clinical efficacy of the anti-osteoporotictive clinical trials.
change in BMD from baseline to endpoint Reference
rtrochanter Total
hip
Distal
radius
Shaft of
radius
Proximal
forearm
Total-body
(Hologic)
4.7*** 1.6*** 1.8*** 29
0.2 30
2.1***y 16
42
3.4****a
2.9****b
33
14
34
8.6***y 35
***y 2.6***y 0.1 2.1 0.6 (Hologic)/3.1
(Lunar)***y
37
other day with 12 doses every 3 months.
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prospective clinical trials.
Effects on fracture risks
Since the objective of osteoporosis treatment in all studies
was to prevent fractures, the methods of assessing vertebral
fractures, involving both semiquantitative and morphometric
evaluations, were similar in these trials (Table 4 [14,16,29,
30,33e35,37,42]).Bisphosphonates
Alendronate
From the analysis of the vertebral fracture arm of the FIT,
the primary endpoint of one or more new radiographic verte-
bral fractures was 47% lower in women given alendronate
than in the placebo group [38]. Compared with the placebo
arm, significantly fewer women in the alendronate group had
clinical vertebral fractures. In terms of non-vertebral fractures,
there was no significant difference between patients receiving
alendronate and patients in the placebo arm.
Risedronate
The VERT-NA study found the cumulative incidence of
new vertebral fractures during a 3-year risedronate treatment
regimen was lower by 49%, and there was a 33% reduction in
nonvertebral fractures compared with the placebo [24]. The
VERT-MN study report shows that the reduction of fracture
risk was observed in the first year to be 61%. Comparing with
the control arm, the vertebral and non-vertebral fracture risk in
the risedronate 5 mg group was reduced by 49% and 33%,
respectively. An extension study of the VERT-MN trial, with
only one-third of the women randomized in the original study,
demonstrated a continuing effect on the reduction of new
vertebral fractures (59% reduction in risk; P ¼ 0.01) [51]. A
pooled summary of these two randomized studies indicated
a risk reduction of new vertebral fractures by 62% and of
multiple new vertebral fractures by 90% after treatment with
risedronate 5 mg/day for 1 year versus the control [52].Table 4
Summary of antifracture efficacy of antiosteoporotic therapies from prospective cl
Agent Trial Fracture End
Point (duration)
Fracture with
Treatment n/N (%)
F
P
Bisphosphonate
Alendronate FIT-1 Vertebral (3 Y) 78/1022 (8.0) 1
Risedronate VERT-NA Vertebral (3 Y) 61/540 (11.3) 9
VERT-MN Vertebral (3 Y) 53/293 (18.1) 8
Vertebral (5 Y) 15/109 (13.8) 2
Ibandronate 2.5 mg BONE Vertebral (3 Y) NA (4.68) N
Ibandronate 20 mg BONE Vertebral (3 Y) NA (4.90) N
Raloxifene MORE Vertebral (3 Y) 113/769 (14.7) 1
Calcitonin PROOF Vertebral (5 Y) 51/287 (18) 7
Strontium Ranelate SOTI Vertebral (3 Y) 150/719 (20.9) 2
Teriparatide FPT Vertebral (21 M) 22/444 (5.0) 6
Antivertebral fractures efficacy from of antiosteoporotic prospective clinical trials
treatment group, n ¼ patient number of incident fractures, RR ¼ relative risk.Ibandronate
With regard to the effect on new vertebral fracture reduc-
tion, the BONE study observed a significant reduction in the
relative risk of new or worsening vertebral fractures after
a 2-year treatment with ibandronate [42]. At the end of the
study, the relative risk reductions compared with the placebo
were 62% and 50% for the daily and intermittent groups,
respectively. An effect of ibandronate on the risk of a new
clinical vertebral fracture was also found. Nevertheless,
a significant relative risk reduction of clinical non-vertebral
fractures was found only in those patients with a baseline
femoral neck BMD T-score less than e3.0 and who were
treated with oral daily ibandronate [53].
Raloxifene
In the MORE study, the reduction in the relative risk of one
or more new vertebral fractures for the subset of women with
prevalent vertebral fractures and daily treatment with 60 mg of
raloxifene was 30% [22]. In addition, women receiving
raloxifene had a risk reduction in non-vertebral fractures,
although the results were from an analysis of pooled ralox-
ifene groups.
Strontium ranelate
For strontium ranelate, the effect on fracture reduction was
apparent from the end of the first year of treatment. Over the
entire 3-year study period, patients in the strontium ranelate
group had a 41% lower risk of a new vertebral fracture than
those in the placebo group [44]. A new fracture diagnosed by
quantitative assessment was confirmed by semi-quantitative
evaluation, as well.
Calcitonin
Compared with the placebo, there was a 33% reduction in
the relative risk of developing a new vertebral fracture in
patients treated with calcitonin 200 IU, and the number of
multiple new vertebral fractures was reduced by 35% [43].
Compared with the placebo, there was a nonsignificant
reduction in the risk of non-vertebral fractures and hip frac-
tures in the calcitonin 200-IU group.inical trials.
racture with
lacebo n/N (%)
Absolute
risk reduction
RR of Fracture
(95% CI)
p value Reference
45/1005 (15.0) 7.0 0.53 (0.41e0.68) <0.001 29
3/571 (16.3) 5.0 0.59 (0.43e0.82) 0.003 30
9/307 (29.0) 10.9 0.51 (0.36e0.73) <0.001 16
9/103 (28.2) 11.8 0.41 (0.21e0.81) 0.01 42
A (9.56) 4.88 0.38 (0.25e0.59) 0.0001 33
A (9.56) 4.66 0.50 (0.34e0.74) 0.0006 33
63/770 (21.2) 6.5 0.7 (0.6e0.9) 14
0/270 (26) 8 0.67 (0.47e 0.97) 0.03 34
37/723 (32.8) 11.9 0.59 (0.48e0.73) <0.001 35
4/448 (14.3) 9.3 0.35 (0.22e0.55) <0.001 37
[3e35,37,42] CI ¼ confidence interval, M ¼ months, N ¼ patient number in
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For recurrent vertebral fractures, the teriparatide 20 mg
daily dose reduced the risk of one or more fractures and two or
more fractures by 65% and 77%, respectively [46]. Further-
more, women treated with the 20-mg dose of teriparatide were
35% and 53% less likely to have 1 or more new non-vertebral
fractures and fragility fractures, respectively. Based on the
information of cumulative incidence, the protective effects of
parathyroid hormone treatment became evident after 9e12
months. The incidence of new hip fractures was not signifi-
cantly different between the treatment group and the placebo
group; however, this finding was probably related to the small
numbers when performing analysis by the site of fracture.
Summary of effects on antifracture risks
All of these antiosteoporotic fracture studies provided
strong evidence to support an absolute reduction in the
occurrence of any new vertebral fracture in the previously
fractured studied population compared with the placebo pop-
ulation, ranging from one-third to more than three-fourths
(Fig. 2). However, the effects on the reduction of non-
vertebral fractures are not so significant. The main reason is
that they are rare events; in the majority of anti-fracture site-
specific analyses, the small number of hip fractures usually
precluded a meaningful statistical analysis.
Effects on back pain
Chronic back pain associated with or without vertebral
fracture is a great challenge to health care professionals and
profoundly affect the quality of life to the patients. Emerging
evidence suggests that, in addition to reducing the incidence of
vertebral fractures, calcitonin, intravenous bisphosphonates,
strontium ranelate, and teriparatide may also have a direct
effect on bone pain [54].Strontium ranelateOver the 3-year treatment period, back pain was reported
by 17.7% of the women in the strontium ranelate group and byFig. 2. All of these anti-osteoporotic fracture studies provided strong evidence
to support an absolute reduction in the occurrence of any new vertebral
fracture in the previously fractured studied population compared with the
placebo population, ranging from one-third to more than three-fourths.21.3% in the placebo group (P ¼ 0.07) [44]. The number of
patients without back pain was significantly increased by 30%
(P ¼ 0.005) [55]. More patients were without back pain
(P ¼ 0.005) with strontium ranelate than with the placebo over
a 4-year period [56].TeriparatidePatients in the pooled teriparatide group had reduced risk
for any back pain [relative risk, 0.73 [95% confidence interval
(CI) ¼ 0.61-0.87], moderate or severe back pain [0.72
(CI ¼ 0.58-0.89)], and severe back pain [0.39 (CI ¼ 0.25-
0.61)] compared with pooled controls, from initiation of the
study to the end of follow-up [57].
The European Forsteo Observational Study (EFOS) was
a prospective observational study to observe the effects of
teriparatide in 1648 postmenopausal women with osteoporosis
treated for up to 18 months in European countries [58]. In this
study, more than 90% of enrolled patients had a previous
fracture, so they were as high risk a population as the patients
in the FPT. The study found that mean back pain 100 mm
Visual Analogue Scale (VAS) was reduced by 25.8 mm at the
endpoint (P < 0.001), and mean change from baseline in VAS
was 13 mm by 18 months.
In addition, teriparatide treatment was shown to be asso-
ciated with significant reductions in back pain, regardless of
the presence of recent vertebral fracture. Five hundred three
patients who received teriparatide for up to 2 years showed
that those with a recent vertebral fracture had a greater
decrease in back pain than those without (P < 0.05) and those
with and without mild back pain (30 mm); those with and
without severe back pain (60 mm) at baseline all had
a statistically significant reduction in back pain after 24
months (P < 0.05) [59].
Effects on quality of life
Health-related quality of life (HRQoL) is a multidimen-
sional health concept that mainly represents subjective
symptoms that may influence the sense of well-being and day-
to-day function. Physical capacity is one of the essential
factors for maintaining well-being. An undiagnosed or
untreated vertebral fracture may lead to chronic pain, bone
deformity, or a compromise of daily performance and activity,
and potentially a progression of disability in maintaining
personal or social roles [60]. Vertebral fractures have been
proven to be associated with a deterioration of quality of life
among post-menopausal women with osteoporosis [61].
There have been numerous instruments for investigating
HRQoL. Because of the heterogeneity of the evaluation
instruments, it is difficult to make a direct comparison among
the antiosteoporotic trials.
The inconsistent results from the two questionnaires were
explained to be associated with the differences between the
generic and disease-specific instruments.
A Prospective Observational Scientific Study Investigating
Bone Loss Experience (POSSIBLE US), enrolling 5015
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to and stable on osteoporosis therapies at study entry and in
the following year [62,63]. The data examined included
patient reports of gastrointestinal adverse events overall and
by drug class (bisphosphonates, such as alendronate, risedro-
nate, ibandronate vs. non-bisphosphonates, such as oral or
transdermal postmenopausal estrogen, raloxifene, calcitonin,
teriparatide, or calcium and/or vitamin D only), and the
association between gastrointestinal adverse events and
medication discontinuation, HRQoL, and treatment satisfac-
tion [63]. Women new to osteoporosis therapy with gastroin-
testinal adverse events at month 6 had lower mean HRQoL
(OPAQ-SV Emotional Status: 72.3 vs. 78.2, P ¼ 0.005) and
treatment satisfaction scores (adverse events: 71.4 vs. 82.9;
efficacy: 58.6 vs. 65.6; global: 55.0 vs. 64.4; all P  0.02) than
those without gastrointestinal adverse events. Women report-
ing any gastrointestinal adverse event had a higher therapy
discontinuation rate than those without gastrointestinal
adverse events (6-month OR ¼ 1.39, 95% CI: 1.05-1.84;
12-month OR ¼ 1.30, 95% CI: 1.03-1.63; both P  0.03),
which suggested that gastrointestinal adverse events were
more common in bisphosphonate than nonbisphosphonate
users, and were associated with increased therapy discontin-
uation [63].Strontium ranelateIn the SOTI study, the SF-36 questionnaire and
osteoporosis-specific QUALIOST (The QUAlity of Life
questionnaire In OSTeoporosis) were used to evaluate the
impact of strontium ranelate versus placebo on HRQoL [55].
The score changes in the SF-36 from baseline to endpoint
showed deteriorations in HRQoL in both the strontium rane-
late and placebo groups. There were also no significant
between-group differences in any of the individual scores, in
either the mental or physical component. The QUALIOST
scores in patients treated with strontium ranelate versus the
placebo group showed a significantly negative change (total
score, emotional dimension, physical dimension; P ¼ 0.028,
P ¼ 0.024, P ¼ 0.046, respectively) demonstrating that an
improvement in HRQoL was observed in the treated group.
Teriparatide
In the EFOS, HRQoL was measured by using the European
Quality of Life Questionnaire (EQ-5D) [58]. After 18 months,
fewer patients reported the need to assist themselves with their
arms when standing up from a chair (54.6%), compared with
baseline (62.9%) (P < 0.001).
Safety and adherence
Most of the apparent adverse effects related to anti-
osteoporotic medication are associated with their administra-
tion pathway. However, some might be related to the drugs or
medication themselves.BisphosphonatesGastrointestinal adverse events have been shown to affect
the tolerability and compliance of alendronate [64,65].
However, the frequency of upper gastrointestinal adverse
events was reported to be comparable in the placebo and
treatment arms in the FIT-VFA, VERT, and BONE trials
[24,38,39,42]. The report on adverse events from the FIT-VFA
study showed that there were no significant differences in
adverse events between the alendronate group and the placebo
group, including upper gastrointestinal problems [38]. It is
noteworthy that the proportion of upper gastrointestinal
problems in both the placebo arm and the alendronate arm was
more than 40%. In the VERT-NA and VERT-MN studies,
there was a similar incidence of adverse events in the risedr-
onate and placebo groups, but the percentage of upper
gastrointestinal tract events in both groups was around 30%
[24,39]. In the VERT-NA study, the proportion of subjects that
withdrew was as high as 40%, and digestive complaints were
the commonest reason for study discontinuance, accounting
for 36% in the risedronate group [39]. In addition, oral
bisphosphonates are known to cause serious esophagitis in
some users [66]. It has been long considered that there is
a close correlation between esophagitis and esophageal cancer,
especially in those in which esophagitis related to reflux is an
“established risk factor” for esophageal cancer through the
Barrett pathway. Therefore, it is rationale to suppose the
possibility of an increased risk of esophageal cancer in oral
bisphosphonate users. In fact, Wysowski [67] published the
first-ever report on cases of esophageal cancer in users of oral
bisphosphonates in 2009. However, a recent large cohort study
from the United Kingdom showed that oral bisphosphonates
are not significantly associated with esophageal or gastric
cancer (the adjusted hazard ratios for the risk of esophageal
and gastric cancer combined and for the risk of esophageal
cancer alone were 1.19 (95% CI, 0.69e2.05) and 1.23 (95%
CI, 0.66e2.30), respectively, for any bisphosphonate use) [64].
Since 2002, osteonecrosis of the jaw (ONJ) has been linked
to the use of bisphosphonates [25]. The definition of
bisphosphonate-associated ONJ is the presence of necrotic
bony tissue in the jaw or face for at least 8 weeks in a patient
who has been treated with a bisphosphonate, but has not been
exposed to radiation therapy. The mechanism of
bisphosphonate-related ONJ is not completely understood.
Two new studies [68,69] found no increase in jaw surgery for
inflammatory conditionsda proxy for ONJdwith oral
bisphosphonates, but the risk of jaw necrosis was increased
almost eight times in those receiving intravenous
bisphosphonates.
The risk of atrial fibrillation with alendronate may be
increased in the first weeks of treatment [70,71], but no excess
risk was seen in long-term users based on the General Practice
Research Database (GPRD; a self-controlled case-series
analysis of 40,253 women who were prescribed bisphospho-
nates), since the incidence rate ratio was 1.07 (95% CI
0.94e1.21) for development of atrial fibrillation (2195 patients
who developed atrial fibrillation within the predefined study
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unexposed periods [72].
There is a concern about renal adverse events in patients
with osteoporosis treatment. Although bisphosphonates have
not been associated with renal adverse events in patients with
a clearance of creatinine (CCr) above 30e35 ml/minute, FDA
product labeling states that it is not recommended to use these
medications in patients with a lower CCr due to the lack of
experience with such patients [70]. A retrospective analysis of
the FIT data revealed no difference in the incidence of adverse
events in the treatment groups regardless of renal function, and
therapy was as effective in terms of preservation of BMD and
reduction of fractures [73]; however, the data regarding the use
of bisphosphonates in patients with more severe chronic
kidney disease and in end-stage renal failure (CCr < 15 ml/
minute) are not available.
Three recent publications focusing on the adverse events
with long-term use of bisphosphonates might help the audi-
ence become familiar with these types of anti-osteoporotic
medication [71,74,75].
Raloxifene
The most common adverse effects of raloxifene treatment,
compared with the placebo, were hot flashes and leg cramps
[28]. The elevated risk of venous thromboembolic events or
endometrial cancer with tamoxifen treatment [76] was not
found in the STAR study. In addition, the occurrence of breast
cancer was less frequent in the women receiving raloxifene in
the MORE study (RR, 0.38; 95% CI, 0.24e0.58 for pooled
dose vs. placebo) [77]. An extension study of the MORE
studydthe Continuing Outcomes Relevant to Evista
(CORE)dconfirmed a significant reduction in the incidence of
invasive breast cancer and ER-positive invasive breast cancer
during 8 years of raloxifene treatment, with no safety concerns
[78,79].
Calcitonin
The only significantly increased adverse effect reported in
the PROOF trial of calcitonin nasal spray was rhinitis;
however, 97% of nasal events in the calcitonin-treated groups
were of mild or moderate severity [43].
Teriparatide
The compliance issue with teriparatide is related to its
administration by subcutaneous injection. The average rate of
compliance ranged from 79%e83% at each follow-up visit,
and the rates did not significantly differ between the treatment
group and the placebo group [46].
Cost-effectiveness of osteoporosis treatment
Osteoporotic fragility fractures constitute a significant
public health concern. Since the lifetime risk of any osteo-
porotic fracture is very high (40%e50% in women and 13%e
22% in men), fractures are associated with significant
mortality and morbidity and represent a substantial economic
burden to society [80]. However, direct comparisons of thecost-effectiveness of different kinds of antiosteoporotic drugs
or among different populations or countries are not available;
therefore, the following data presentations should be used with
caution.BisphosphonatesA recent publication discussed the cost-effectiveness of the
use of bisphosphonates in the treatment or prevention of
osteoporosis [80], suggesting the cost-effectiveness might vary
in different populations and different countries. For example,
among women with low BMD and previous fractures,
bisphosphonate therapy was most cost-effective in those
populations aged 70 years, and unlikely to be cost-effective
in populations aged 50 years; there was uncertainty con-
cerning the cost-effectiveness in populations aged 60e69
years. Furthermore, in women with low BMD without
previous fractures, treatment with alendronate or risedronate
appeared to be cost-effective across countries (like the United
Kingdom, the United States, and Denmark), but there was
some uncertainty about the cost-effectiveness of etidronate in
patients in the highest age groups. In women with osteopenia,
alendronate therapy may be cost-effective in women with a T-
score of e2.4 in the United States. Screening for low BMD
and treatment with alendronate or etidronate appear to be cost-
effective in postmenopausal women in general and in women
with rheumatoid arthritis initiating corticosteroid therapy.
Alendronate therapy without screening was also shown to be
potentially cost-effective in certain at-risk male populations, as
well as in women initiating corticosteroid therapy after the age
of 40 years.Strontium ranelateBased on six studies [81], strontium ranelate is a cost-
saving drug for women with osteoporosis aged over 80
years, and is a cost-effective treatment compared with no
treatment for osteoporotic women aged over 70 years and for
younger women with clinical risk factors for fragility frac-
ture. Strontium ranelate was also cost-effective compared
with branded risedronate in osteoporotic women aged over
75 years [82].RaloxifeneTo identify cost-effective scenarios of raloxifene treatment
compared with no treatment in younger postmenopausal
women at increased risk of invasive breast cancer and with
a fracture risk below 20%, a microsimulation model populated
with data specific to American Caucasian women was used to
quantify the costs and benefits of 5-year raloxifene treatment.
The population evaluated was selected based on 10-year major
fracture probability as estimated with the FRAX(R) being
below 20% and a 5-year invasive breast cancer risk as esti-
mated with the Gail risk model ranging from 1%e5%. The
conclusions revealed that raloxifene is potentially cost-
effective in cohorts of young postmenopausal women who
163M.-H. Cheng et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 153e166do not meet the suggested National Osteoporosis Foundation
10-year fracture risk threshold, and that this cost-effectiveness
is contingent on the 5-year invasive breast cancer risk of these
women [83]. In addition, a systematic review and economic
evaluation of alendronate, etidronate, risedronate, raloxifene
and teriparatide for the prevention and treatment of post-
menopausal osteoporosis, based on 90 randomized controlled
trials, showed that only raloxifene appeared to reduce the risk
of vertebral fracture in postmenopausal women unselected
for low BMD [84], suggesting a rationale for the use of
raloxifene in the prevention of both osteoporosis and breast
cancer [28].
In summary, all interventions, including alendronate,
etidronate, risedronate, raloxifene, strontium ranelate, and
teriparatide provided gains in quality-adjusted life-years
compared with no treatment in women with sufficient calcium
and vitamin D intakes. The size of the quality-adjusted life-
years gain for each intervention was strongly related to the age
of the patients, because the estimated costs varied widely for
the interventions and these net costs were markedly different
by age, with some interventions becoming cost-saving at
higher age ranges in patients with a prior fracture [84].
Discussion
Osteoporotic fracture, a debilitating condition with
significant morbidity and mortality, has important implica-
tions for public health. Given the lack of head-to-head
comparison trials, indirect comparison of various anti-
osteoporosis treatments may be an alternative way to develop
a preliminary idea. Although all the antiresorptive agents
were of the same treatment duration, direct comparisons
cannot be made, there are several limitations to be taken into
account, such as differences in study design may have
contributed to the heterogeneity of the results. Discrepancies
in patient populations or baseline disease severity including
fracture risk limit comparisons. The interpretation of study
results is also complicated by the pooling of dosage groups,
the changing of dosage during the study, or a post-hoc
analysis of subpopulations [24,52]. Of note, some biologic
outcomes were disclosed using a per-protocol analysis
instead of an intent-to-treat population, so a parallel should
be drawn with caution [42]. Furthermore, although random-
ized controlled trials are considered as the gold standard for
investigating drug efficacy, their design limits a reflection of
the results to the real world.
The definition of osteoporosis continues to evolve as we
gain a better understanding of the underlying changes in bone
and the mechanisms for those alterations. Osteoporosis is
defined as a skeletal disorder characterized by compromised
bone strength, and bone strength reflects the integration of
bone density and bone quality [85]. Currently, the mainstream
method for diagnosis of osteoporosis is the measurement of
BMD using dual-energy X-ray absorptiometry (DXA). BMD
is indeed a good predictor of bone strength. However, bone
strength is not only determined by BMD values, but also
various parameters such as bone geometry and bonemorphology [86]. Although the majority of antiosteoporosis
studies used BMD as the primary endpoint and regarded BMD
as an indicator of treatment response, BMD may not be the
most appropriate measure to evaluate the response to therapy.
For example, in the histomorphometric trial investigating the
effect of teriparatide on bone remodeling, the discordance
existed between the alteration of bone formation indices and
the magnitude of BMD change [49]. Furthermore, the effect of
fracture reduction is not clearly related to an increase in BMD.
For example, fluoride induced a remarkable increase in BMD
but did not reduce the incidence of BMD [87e90]. In this
review, the much greater reduction in the vertebral fracture
risk than the increase in lumbar spine BMD also echoed such
a discrepancy.
Still, the patients in the majority of antiosteoporosis trials
were predominantly Caucasians. However, there is some
evidence showing an ethnic difference in the incidence of
postmenopausal complaints, such as Asian women experi-
encing fewer vasomotor symptoms [91,92]. Whether any
ethnic difference exists in the antiosteoporosis treatments is
still unknown and should be answered only by a placebo-
controlled trial conducted in an Asian population.
Many research institutes and industries have continued their
efforts in exploring novel antiosteoporosis agents. Non-
pharmacologic adjustments include optimizing calcium intake
from dietary sources, engaging in adequate weight-bearing
physical activities, acquiring a proper amount of sun exposure,
improving lighting in a gloomy room, keeping the floor clear of
obstructions, and enhancing the public awareness of osteopo-
rosis. In addition, adequate supplementation of calcium and
vitamin D is essential for individuals with osteoporosis.
Supplementationof vitaminDand calciumhas been proven to be
an effectivemodality to reduce the risk of hip fracturesmodestly
[93]. An adequate daily intake of calcium is 1000 mg for adults
up to the age of 50, and 1200mg for adults older than 50 years of
age [94]. The National Osteoporosis Foundation recommends
a calcium intake of at least 1200 mg and a vitamin D intake of
800e1000 IU per day for postmenopausal women [95]. The
combination of pharmacologic and non-pharmacologic
approaches should provide the most beneficial effects in the
prevention of fractures in patients with osteoporosis.
Conclusions
Since osteoporosis may be considered as a part of the aging
process globally, treatment of patients with pre-existing frac-
ture should have the priority in utilization of medical
resources. Direct comparison between different strategies and
a consideration for different populations and countries might
provide a more concise and reasonable direction in the
management of the women with pre-existing osteoporotic
fracture.
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